md-medicaldata

Authors

 

Jelena Dević

Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Univerzitetsko klinički centar Vojvodine, Hajduk Veljkova 1, Novi Sad

 

UDK: 616-008.9:577.125(497.113)
616.153-78:547.922(497.113)

TThe paper was received / Rad primljen: 04.12.2022.

Accepted / Rad prihvaćen: 25.12.2022.

 

Correspondence to:

Jelena Dević
Kralja Petra Prvog 39
21203 Veternik
063 571148
e-mail: jela.devic@gmail.com

 

 

Sažetak

 

 

Uvod: Porodična hiperholesterolemija (eng. Familiary hypercholesterolemia - FH) je autozomno dominantni poremećaj koji dovodi do smanjenog uklanjanja LDL-a. Prema vodičima kod homozigotne FH indikovano je započinjanje LDL-afareze u ranom detinjstvu. Za heterozigotnu FH smernice indikuju uvođenje afereze kada se ne postigne terapijski odgovor medikamentoznom terapijom. Cilj rada je da ukaže na značaj i benefite izvođenja procedure LDL-afereze. Materijal i metode:  Retrospektivna studija kojom je obuhvaćeno 11 pacijentata kod kojih je sprovedena LDL-afareza u okviru lečenja familijarne hiperholesterolemije. Rezultati: Prosečna vrednost inicijalnih vrednosti ukupnog holesterola je iznosila 8,1 ± 2,3 mmol/L, triglicerida 1,5 ± 1 mmol/L, HDL-a 1,2 ± 0,3 mmol/L, LDL-a 6,2 ± 2,2 mmol/L, non-HDL-a 6,9 ± 2,2 mmol/L, apoA 1,3 ± 0,2 mmol/L, apoB 1,6 ± 0,5 mmol/L, Lp (a) 0,4 ± 0,2 mmol/L i LDL/HDL 5,2 ± 2,7. Utvrđena je statistički značajna razlika pre i nakon LDL-afareze sledećih vrednosti: ukupni holesterol (7,7 ± 1,7 vs. 3,2 ± 0,9 mmol/L; p<0,01), triglicerida (1,7 ± 0,6 vs. 1 ± 0,36 mmol/L; p<0,01), HDL-a (1,4 ± 0,5 vs 1,07 ± 0,3 mmol/L; p<0,01), LDL-a (5,6 ± 1,8 vs. 1,67 ± 0,9 mmol/L ; p<0,01), non-HDL-a (6,3±1,7 vs. 2,2 ± 0,9 mmol/L; p<0,01). apoA (1,5±0,5 vs. 1,2±0,3 mmol/L; p<0,01), apoB (1,6 ± 0,4 vs. 0,5 ± 0,1 mmol/L; p<0,01). LpA (0,5 ± 0,3 vs. 0,2±0,1 mmol/L; p<0,01) i LDL/HDL (5,2 ± 2,7 vs. 4,3 ± 1,8; p<0,01). Zaključak: LDL-afareza je metoda koja značajno snižava parametre lipidnog statusa, na osnovu čega indirektno možemo zaključiti o značaju kliničkog benefita ove metode..

 

Ključne reči:

LDL-afareza; LDL; familijarna hiperholesterolemija

 

 

 

Abstract

Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant disorder that results in decreased LDL removal. According to the guidelines, LDL apheresis is indicated for homozygous FH in early childhood. For heterozygous FH guidelines indicate the introduction of apheresis when an adequate therapeutic response to drug therapy is not achieved. The aim of this paper is to point out the importance and benefits of performing the LDL apheresis procedure. Material and methods: A retrospective study of 11 patients who underwent LDL apheresis in the treatment of familial hypercholesterolemia. Results: The average value of the initial values ​​of total cholesterol was 8.1±2.3 mmol/L, triglycerides 1.5±1 mmol/L, HDL 1.2±0.3 mmol/L, LDL 6, 2±2.2 mmol/L, non-HDL 6.9±2.2 mmol/L, apoA 1.3±0.2 mmol/L, apoB 1.6±0.5 mmol/L, Lp (a) 0.4±0.2 mmol/L and LDL / HDL 5.2±2.7. A statistically significant difference was found before and after LDL apheresis of the following values: total cholesterol (7.7±1.7 vs. 3.2±0.9 mmol/L; p <0.01), triglycerides (1.7±0.6 vs. 1±0.36 mmol/L; p <0.01), HDL (1.4±0.5 vs 1.1± 0.3 mmol/L; p <0.01) , LDL (5.6 ± 1.8 vs. 1.67±0.9 mmol/L; p <0.01), non-HDL (6.3±1.7 vs. 2.2±0.9 mmol/L; p <0.01). apoA (1.5±0.5 vs. 1.2±0.3 mmol/L; p <0.01), apoB (1.6±0.4 vs. 0.5±0.1 mmol/L) p <0.01). LpA (0.5±0.3 vs. 0.2±0.1 mmol/L; p <0.01) and LDL/HDL (5.2±2.7 vs. 4.3±1.8; p <0.01). Conclusion: LDL-apheresis is a therapeutic method that significantly reduces the parameters of lipid status, based on which we can indirectly conclude about the importance of clinical benefits of this method..

 

Key words:

LDL apheresis; LDL; familial hypercholesterolemia

 

 

 

 

References:

1. Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R. LDL-apheresis: technical and clinical aspects. ScientificWorldJournal. 2012; 2012:314283.
2. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016 Jun;31(3):149-62.
3. Wang A,  Richhariya A, Gandra SR, Calimlim  B, Kim L, Quek RG, Nordyke RJ, Toth PP. Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. J Am Heart Assoc. 2016; 5:e003294
4. Bulut M, Nisli K, Dindar A. The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center. Ann Pediatr Cardiol. 2020;13(2):111-116.
5. Thompson G, Parhofer KG. Current Role of Lipoprotein Apheresis. Curr Atheroscler Rep. 2019;21(7):26.
6. Lefort B, Saheb S, Bruckert E, Giraud C, Hequet O, Hankard R. Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia. Atherosclerosis. 2015; 239:158–62.
7. Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. The German lipoprotein apheresis registry (GLAR)- almost 5 years on. Clin Res Cardiol Suppl. 2017;12(1):44–9.
8. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPAvariants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018; 3:619–27.
9. Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016; 37:3588–95.
10. Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion. 2006;73(4):259–64.
11. Chang CT, Tsai TY, Liao HY, Chang CM, Jheng JS, Huang WH, et al. Double filtration plasma apheresis shortens hospital admission duration of patients with severe hypertriglyceridemia-associated acute pancreatitis. Pancreas. 2016; 45:606–12.
    

PDF: 02-Dević J. MD-Medical Data 2022;14(3) 065-068.pdf